Belluscura (LSE:BELL) EBIT per Share: £-0.10 (TTM As of Jun. 2024)


What is Belluscura EBIT per Share?

Belluscura LSE:BELL EBIT per Share is £-0.10 as of Jun. 2024.

Belluscura's EBIT per Share for the six months ended in Jun. 2024 was £-0.03. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.10.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Belluscura's EBIT per Share or its related term are showing as below:

LSE:BELL's 3-Year EBIT Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Belluscura's EBIT for the six months ended in Jun. 2024 was £-4.74 Mil.

Belluscura  (LSE:BELL) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Belluscura EBIT per Share Related Terms

Belluscura EBIT per Share Historical Data

* Premium members only.

The historical data trend for Belluscura's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belluscura EBIT per Share Chart

Belluscura Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT per Share
Get a 7-Day Free Trial -0.01 -0.01 -0.04 -0.05 -0.11

Belluscura Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.03 -0.02 -0.04 -0.07 -0.03

Belluscura EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Belluscura's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

EBIT per Share(A: Dec. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-13.975/131.949
=-0.11

Belluscura's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

EBIT per Share(Q: Jun. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-4.737/171.329
=-0.03

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of £-0.10 mean?
Belluscura (LSE:BELL) has a EBIT per Share of £-0.10 as of Jun. 2024. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Belluscura and its competitors.
Is Belluscura's EBIT per Share too high?
Belluscura's current EBIT per Share is £-0.10.
How does Belluscura's EBIT per Share compare to ABT and BSX?
Belluscura's EBIT per Share of £-0.10 can be compared against companies in the Medical Devices & Instruments industry. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Belluscura and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Belluscura's current EBIT per Share is £-0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belluscura stock overvalued right now?
Belluscura (LSE:BELL) has a current EBIT per Share of £-0.10. The current EBIT per Share is £-0.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Belluscura (LSE:BELL), the current EBIT per Share is £-0.10 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belluscura Business Description

Address 15 Fetter Lane, Holborn, London, GBR, EC4A 1BW
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company has only one operating segment being the sale of oxygen concentrators in the United States. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.